Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine

Home  /  National Uptake and Case Studies  /  Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine
CountryAgencyStatusLinkDetails on adaptation processContact information
(Scotland)HISPublished July 2015Link to reportThe EUnetHTA report was referenced in discussion on impact of sorafenib on health related quality of life. Jan Jones
janjones@nhs.net
BelgiumRIZIVUsed in cross-checking evidence.Francis Arickx
francis.arickx@riziv.fgov.be
PortugalINFARMEDUsed in direct decision-making.João Martins
joao.martins@infarmed.pt
SlovakiaMoH SKUsed in direct decision-making.Tomas Tesar
tomas.tesar@union.sk
SpainIACSUsed in direct decision-making.Almudena Albertos
aalbertos@isciii.es
BelgiumKCELink to summaryAnalysis of scientific context and its relevance, "KCE has read for you".Patrice Chalon
patrice.chalon@kce.fgov.be
CroatiaAAZ2015Summary of information from the report for decision makers and websiteMirjana Huic (Mirjana.Huic@aaz.hr)